Cargando…

Impact analysis of heart failure across European countries: an ESC‐HFA position paper

Heart failure (HF) is a long‐term clinical syndrome, with increasing prevalence and considerable healthcare costs that are further expected to increase dramatically. Despite significant advances in therapy and prevention, mortality and morbidity remain high and quality of life poor. Epidemiological...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosano, Giuseppe M.C., Seferovic, Petar, Savarese, Gianluigi, Spoletini, Ilaria, Lopatin, Yuri, Gustafsson, Fin, Bayes‐Genis, Antoni, Jaarsma, Tiny, Abdelhamid, Magdy, Miqueo, Arantxa Gonzalez, Piepoli, Massimo, Tocchetti, Carlo G., Ristić, Arsen D., Jankowska, Ewa, Moura, Brenda, Hill, Loreena, Filippatos, Gerasimos, Metra, Marco, Milicic, Davor, Thum, Thomas, Chioncel, Ovidiu, Ben Gal, Tuvia, Lund, Lars H., Farmakis, Dimitrios, Mullens, Wilfried, Adamopoulos, Stamatis, Bohm, Michael, Norhammar, Anna, Bollmann, Andreas, Banerjee, Amitava, Maggioni, Aldo P., Voors, Adriaan, Solal, Alain Cohen, Coats, Andrew J.S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9715845/
https://www.ncbi.nlm.nih.gov/pubmed/35869679
http://dx.doi.org/10.1002/ehf2.14076
Descripción
Sumario:Heart failure (HF) is a long‐term clinical syndrome, with increasing prevalence and considerable healthcare costs that are further expected to increase dramatically. Despite significant advances in therapy and prevention, mortality and morbidity remain high and quality of life poor. Epidemiological data, that is, prevalence, incidence, mortality, and morbidity, show geographical variations across the European countries, depending on differences in aetiology, clinical characteristics, and treatment. However, data on the prevalence of the disease are scarce, as are those on quality of life. For these reasons, the ESC‐HFA has developed a position paper to comprehensively assess our understanding of the burden of HF in Europe, in order to guide future policies for this syndrome. This manuscript will discuss the available epidemiological data on HF prevalence, outcomes, and human costs—in terms of quality of life—in European countries.